MLI Certified

On-Demand Activities

Search
Generic filters
Credit Amount (at least)
Course Types
Learner Specialties
Therapeutics Areas
Episode 3 of 4 of the series on: The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes
Avoiding Roadblocks in Coordinating CAR-T Therapy for B-cell Lymphoma: Practical Tips for Community Oncology Clinicians, episode 3 of the 4-part educational initiative The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes, is designed for community-based oncology clinicians. This CE activity includes conversations among CAR-T experts and a community clinician; it includes patient video clips and numerous downloadable resources including a directory of CAR-T treatment centers organized by state. This activity focuses on managing logistics associated with CAR-T therapy, including common misperceptions, the numerous services offered by treating centers, and how to overcome roadblocks for your patients.
Genomics and Hematologic Malignancies: Beyond the Philadelphia Chromosome
It has been 60 years since the discovery of a chromosomal abnormality in CML; the so-called Philadelphia chromosome. Since then genomics has revolutionized cancer care and the impact in hematologic malignancies is plentiful. Healthcare providers must understand the science to be able to apply in practice and communicate complex information to patients and caregivers. This session will provide an overview of foundational genomic concepts and how genomics is applied across the care continuum for hematologic cancers. Case studies examining the application of testing to “real life” situations will be presented and resources for patients will be shared.
Advancing the Treatment of Pompe Disease: Clinical Updates in Newborn Screening and Enzyme Replacement
In this activity, an expert in Pompe disease discusses the presentation of infantile- and late-onset Pompe disease, as well as treatment via enzyme replacement therapy.
Advancing Treatment of von Willebrand Disease: A Visual Exploration on Personalizing Care with Current and Emerging Management Strategies
In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making.
Determining Which Patients Will Benefit from GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM
In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM.
A New Era of Migraine Management: Recent Updates on Recognition, Acute Treatment and Prevention for Emergency Physicians
In this activity, an expert in emergency medicine discusses the diagnosis and management of patients with migraine in the emergency department setting.
Modern Management of ITP: Thinking Beyond the Conventional Therapies
In this animated, visually-enhanced activity, an expert in hematology-oncology discusses current standards for diagnosing and treating idiopathic thrombocytopenic purpura—and provides an update on the challenges associated with modern care and the promise of novel therapeutic options for disease management.
How I Think, How I Treat - Assessing, Managing and Engaging Patients with Uncontrolled Moderate-to-Severe Asthma: Comparing Approaches with Experts Around the World
In this activity, experts in asthma discuss assessing and managing uncontrolled, moderate to severe asthma for pediatric and adult patients, as well as selecting targeted therapies and improving treatment adherence.
Episode 4 of 4 of the series on: The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes
Opening the CAR(T) Door to Get Patient to Therapy, episode 4 of the 4-part educational initiative The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes, is designed for community-based oncology clinicians. This CE activity includes conversations among CAR-T experts and a community clinician; it includes patient video clips and numerous downloadable resources including a directory of CAR-T treatment centers organized by state. This activity focuses on managing logistics associated with CAR-T therapy, including common misperceptions, the numerous services offered by treating centers, and how to overcome roadblocks for your patients.
A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes
In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis.
Modern Management of ITP: Thinking Beyond the Conventional Therapies
In this animated, visually-enhanced activity, an expert in hematology-oncology discusses current standards for diagnosing and treating idiopathic thrombocytopenic purpura—and provides an update on the challenges associated with modern care and the promise of novel therapeutic options for disease management.
An Animated Exploration of Chronic Fibrosing Interstitial Lung Disease: From Diagnosis to Management in the Era of Antifibrotic Therapy
In this activity, an expert in interstitial lung disease discusses the diagnosis of and novel and emerging therapies to treat chronic fibrosing interstitial lung disease.
Episode 2 of 4 of the series on: The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes
What You MUST Know as More Lymphoma Patients Are on the Road to CAR-T, episode 2 of the 4-part educational initiative The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes, is designed for community-based oncology clinicians. Through interactive discussion among cellular therapy experts and a community-based oncologist, this activity provides practical information regarding management of acute, delayed, and late toxicities of CAR-T therapy and what your patients and their caregivers need to know before, during, and after treatment. Videos, animations, and key learning points address clinical challenges with interprofessional perspectives to foster meaningful change.
Targeting the Burden of Moderate to Severe Psoriasis: A Visual Exploration of the Role of IL-17 Inhibitors in Improving Patient Care and Quality of Life
In this activity, an expert in dermatology discusses the role of IL-17 inhibitors in the treatment of psoriasis.
Applying Evidence to Practice: Updated Consensus Recommendations for the Diagnosis, Surveillance, and Management of Tuberous Sclerosis Complex
In this activity, experts discuss recent updates to recommendations in the diagnosis, surveillance, and management of tuberous sclerosis complex.
Across the Age Spectrum: Expert Insights on Emerging Uses of Targeted Therapy for the Treatment of Uncontrolled Moderate-to-Severe Asthma
In this activity, an expert in pulmonology discusses the latest clinical research and treatment guidelines on approved biologic therapies for the management of adult and pediatric patients with uncontrolled moderate to severe asthma.
Envisioning the Future of Emerging Nonfactor Therapies in Hemophilia A and B: The Art and Science of RNA Interference
In this activity, an expert in hemophilia explores the evidence supporting novel, emerging hemophilia therapeutics and provides guidance on the implications of the evidence presented for real-world practice.
Episode 1 of 2: Talk to Me About Dual Agonists
For prescribers and non-prescribers alike, therapeutic inertia can be a big challenge when trying to optimize therapy to control patients’ glucose levels and improve their overall health. Such obstacles can be even more difficult when trying to switch treatment regimens. Novel therapies can be miracles, but only if patients can actually get them. In Talk to Me About Dual Agonists, episode 1 of the Med Table TalkTM series, certified diabetes care and education specialists address therapeutic inertia and the need to treat the whole person, rather than just A1C. They then explain the mechanisms of action, efficacy and safety, and precautions for using a unimolecular dual agonist and strategies for helping patients gain access.
Visualizing Progress With BTK Inhibitors: An Animated Journey Through the Mechanisms of Covalent and Non-Covalent Options
It’s well known that the BTK inhibitor agent class is highly effective across several B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. Less well understood are the factors that can limit the effectiveness of covalent BTK inhibitors and the emerging strategies that can overcome therapeutic resistance and intolerance, which provide a new option for managing relapsed disease. In this animated, visually enhanced activity, a hematology-oncology expert outlines the clinically relevant mechanistic aspects of covalent and noncovalent BTK inhibitors, mechanisms and patterns of resistance to covalent agents, and rationale for integrating novel approaches to combatting resistance and intolerance.
Easing the Burden of Hypereosinophilic Syndrome: An Animated Exploration of the Role of Targeted Therapy to Improve Patient Outcomes
In this activity, an expert in hypereosinophilic syndrome discusses the burden, symptoms, and differential diagnosis of the disease, as well as the latest data on treatment.
Carrying Through in Advanced/Metastatic Urothelial Carcinoma: Expert Perspectives on Recent Practice‐Changing Data and the Practicalities of Individualizing and Continuing Care With Novel Immunotherapy Maintenance Strategies
Improving outcomes for patients with advanced urothelial carcinoma (UC) has been challenging, with many patients experiencing only short periods of progression-free survival after treatment with first-line chemotherapy. A game changer in many cancers, immunotherapy has provided new avenues for the cancer care team to help their patients with advanced UC live longer. In particular, new data on the use of immunotherapy in the first-line maintenance setting has shown that using immunotherapy before patients’ progress to the second-line setting increases survival without a negative impact on quality of life. In this activity, a panel of experts discusses strategies for incorporating these important data into individualized patient care.
Optimally Sequencing Modern TKIs in GIST: Expert Perspectives From an Interprofessional Sarcoma Team
While TKIs have been a mainstay in the first three lines of treatment for patients with gastrointestinal stromal tumors (GISTs), new discoveries and emerging science have led to the development of newer agents that address treatment resistance. Known as modern TKIs, these agents have a confirmed role in the treatment of patients with specific mutations or in later-line settings and are now being tested in earlier-stage disease. While oncologists, oncology nurses, and other members of the interdisciplinary cancer care team have new opportunities for increasing survival and improving QOL in their patients with unresectable/metastatic GIST, they are also faced with more complex treatment paradigms that must account for mutation profiling, treatment selection/sequencing, symptom and AE management, psychological support, and nutritional considerations. Join our experts to hear how all members of the cancer care team can work together to effectively incorporate these modern TKIs into clinical practice.
Integrating the Latest Evidence into Practice: Expert Insights on Targeted Biologic Therapy for Pediatric and Adult Patients with Moderate to Severe Atopic Dermatitis
In this activity, an expert dermatologist discusses the latest evidence from the 30th European Academy of Dermatology and Venereology Congress for current and emerging targeted biologic therapies for moderate to severe atopic dermatitis in adults and children.
Strategies for Controlling Glucose with MTI
This CME/NCPD/CPE activity includes five individual interactive, microlearning modules addressing care and outcomes for individuals with diabetes treated with mealtime insulin (MTI). The modules incorporate case studies with embedded questions for an active learning experience. Learners can choose to participate in one or more of the modules to address their educational interests and needs based on their scope of practice and patient population.
Scroll to Top